Accelerated partial breast irradiation with interstitial multicatheter brachytherapy after breast-conserving surgery for low-risk early breast cancer

Abstract

Patients with low-risk invasive ductal carcinoma treated with breast-conserving surgery (BCS) were included in a multicatheter brachytherapy APBI protocol. The primary endpoint was ipsilateral breast recurrence. Between December 2008–December 2017, 186 low-risk breast cancer patients were treated with APBI using interstitial multicatheter brachytherapy and followed prospectively. At 5-years of follow-up, cumulative local recurrence (LR) and cause-specific survival was 1.1% (95% CI 0.3–1.9) and 98.3% (95% CI 97.3–99.3%) respectively. No grade 3 adverse effects were observed. Postoperative APBI using multicatheter brachytherapy after BCS in early breast cancer patients have excellent rates of local control and survival, without significant toxicity.

Implementation of accelerated partial breast irradiation at the Oncology Institute of Vojvodina

“…Interstitial brachytherapy was the first APBI technique that was developed [9]. After results of studies with long term follow up, this technique was accepted in experienced centers as comparable to WBI in terms of efficacy and toxicity [9,10].…”

“…Interstitial brachytherapy was the first APBI technique that was developed [9]. After results of studies with long term follow up, this technique was accepted in experienced centers as comparable to WBI in terms of efficacy and toxicity [9,10]. Furthermore, there is a novel approach to delivery of APBI-image guided breast brachytherapy that maintains a high level of precision by using breast immobilization via breast compression and image guidance [11].…”

Ten-Year Results of Accelerated Partial-Breast Irradiation with Interstitial Multicatheter Brachytherapy after Breast-Conserving Surgery for Low-Risk Early Breast Cancer

“…The eligibility and exclusion criteria have already been published [ 17 ]. In short, women aged ≥50 years who were affected by early (pT ≤ 3 cm, pN0, M0) breast cancer and who had undergone BCS, an axillary dissection, or a sentinel node biopsy with microscopically clear resection margins were included.…”

“…The treatment protocol has been previously reported [ 17 ]. In short, all patients had interstitial multiplanar implants to effectively cover the clinical target volume (CTV), including both the surgical cavity and a safety margin (at least 20 mm).…”

“…A follow-up [ 17 ] was performed jointly by the surgeons and medical oncologist from the participating institutions and the treating radiation oncologists. This clinical examination included the documentation of late adverse effects using the CTCAE 4.0 scale.…”